Tumor vasculature targeted therapies. Getting the players organized

Biochemical Pharmacology

Volumn 55, Issue 12, 1998, Pages 1939-1945

  Molema, Grietje ^a,b   Meijer, Dirk K F ^a   De Leij, Lou F M H ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Animal; Human; Target epitopes; Targeting; Tumor; Vasculature

Indexed keywords

EPITOPE; INTEGRIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MITOFLAXONE; PROTEIN TYROSINE KINASE; VASCULOTROPIN;

ANGIOGENESIS; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TUMOR GROWTH; TUMOR VASCULARIZATION;

EID: 0032525740     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00011-2     Document Type: Article

References (55)

1. Molema G, de Leij LFMH, Meijer DKF. Tumor vascular endothelium Barrier or target in tumor directed drug delivery and immunotherapy . Pharm Res. 14:1997;2-10.
2. Meijer DKF, Molema G, Moolenaar F, De Zeeuw D, Swart PJ. (Glyco)-protein drug carriers with an intrinsic therapeutic activity The concept of dual targeting . J Controlled Release. 39:1996;163-172.
3. Kroesen BJ, Helfrich W, Molema G and de Leij L, Bispecific antibodies for the treatment of cancer in experimental animal models and man. Adv Drug Delivery Rev, in press.
4. Meijer DKF, Molema G. Targeting of drugs to the liver. Semin Liver Dis. 15:1995;202-256.
5. Senter PD. Activation of prodrugs by antibody-enzyme conjugates A new approach to cancer therapy . FASEB J. 4:1990;188-193.
6. Frankel A, Fitzgerald D, Siegall C, Press O. Advances in immunotoxin biology and therapy A summary of the Fourth International Symposium on Immunotoxins (Myrtle Beach, South Carolina, USA, June 8-10, 1995) . Cancer Res. 56:1996;926-932.
7. Dewhirst MW, Tso CY, Oliver R, Gustafson CS, Secomb TW, Gross JF. Morphologic and hemodynamic comparison of tumor and healing normal tissue microvasculature. Int J Radiat Oncol Biol Phys. 17:1989;91-99.
8. Jain RK. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 6:1987;559-593.
9. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Delivery Rev. 26:1997;71-90.
10. Folkman J. Addressing tumor blood vessels. Nature Biotech. 15:1997;510.
11. Folkman J. Anti-angiogenesis New concept for therapy of solid tumors . Ann Surg. 175:1972;409-416.
12. Denekamp J. Vascular endothelium as the vulnerable element in tumours. Acta Radiol Oncol. 23:1984;217-225.
13. Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science. 275:1997;547-550.
14. Burrows FJ, Watanabe Y, Thorpe PE. A murine model for antibody-directed targeting to vascular endothelial cells in solid tumors. Cancer Res. 52:1992;5954-5962.
15. Burrows FJ, Thorpe PE. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc Natl Acad Sci USA. 90:1993;8996-9000.
16. Camerer E, Kolsto AB, Prydz H. Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb Res. 81:1996;1-41.
17. Stone MJ, Ruf W, Miles DJ, Edgington TS, Wright PE. Recombinant soluble human tissue factor secreted by Saccharomyces cerevisiae and refolded from Escherichia coli inclusion bodies Glycosylation of mutants, activity and physical characterization . Biochem J. 310:1995;605-614.
18. Hagemeier HH, Vollmer E, Goerdt S, Schulze-Osthoff K, Sorg C. A monoclonal antibody reacting with endothelial cells of budding vessels in tumors and inflammatory tissues, and non-reactive with normal adult tissues. Int J Cancer. 38:1986;481-488.
19. Schlingemann RO, Rietveld FJ, de Waal RM, Bradley NJ, Skene AI, Davies AJ, Greaves MF, Denekamp J, Ruiter DJ. Leukocyte antigen CD34 is expressed by a subset of cultured endothelial cells and on endothelial abluminal microprocesses in the tumor stroma. Lab Invest. 62:1990;690-696.
20. Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Jaffe EA, Old LJ. Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc Natl Acad Sci USA. 89:1992;10832-10836.
21. Burrows FJ, Tazzari PL, Amlot P, Gazdar AF, Derbyshire EJ, King SW, Vitetta ES, Thorpe PE. Endoglin is an endothelial cell proliferation marker that is selectively expressed in tumor vasculature. Clin Cancer Res. 1:1995;1623-1634.
22. Griffioen AW, Coenen MJH, Damen CA, Hellwig SMM, van Weering DHJ, Vooys W, Blijham GH, Groenewegen G. CD44 is involved in tumor angiogenesis An activation antigen on human endothelial cells . Blood. 90:1997;1150-1159.
23. Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci USA. 87:1990;7235-7239.
24. Epstein AL, Khawli LA, Hornick JL, Taylor CR. Identification of a monoclonal antibody, TV-1, directed against the basement membrane of tumor vessels, and its use to enhance the delivery of macromolecules to tumors after conjugation with interleukin 2. Cancer Res. 55:1995;2673-2680.
25. Kairemo K, Ljunggren K, Strand SE, Hiltunen J, Penttila P, Nikula T, Laine A, Wahlstrom T. Radioimmunotherapy with 90Y-labeled monoclonal antibodies in a nude mouse ovarian cancer model. Acta Oncol. 32:1993;801-805.
26. Goldberg ID and Rosen EM (Eds.), Regulation of Angiogenesis, EXS Series, Vol. 79. Birkhauser, Basel, 1997.
27. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 339:1989;58-61.
28. Battegay EJ. Angiogenesis Mechanistic insights, neovascular diseases, and therapeutic prospects . J Mol Med. 73:1995;333-346.
29. Brooks PC. Role of integrins in angiogenesis. Eur J Cancer. 32A:1996;2423-2429.
30. Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, Gendron-Maguire M, Gridley T, Wolburg H, Risau W, Qin Y. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature. 376:1995;70-74.
31. Stetler-Stevenson WG. Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. Am J Pathol. 148:1996;1345-1350.
32. 3 for angiogenesis. Science. 264:1994;569-571.
33. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA. 93:1996;14765-14770.
34. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 362:1993;841-844.
35. Jakeman LB, Winer J, Bennett GL, Altar CA, Ferrara N. Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J Clin Invest. 89:1992;244-253.
36. Ferrara N, Keyt B. Vascular endothelial growth factor Basic biology and clinical implications . EXS. 79:1997;209-232.
37. Brown LF, Detmar M, Claffey K, Nagy JA, Feng D, Dvorak AM, Dvorak HF. Vascular permeability factor/vascular endothelial growth factor A multifunctional angiogenic cytokine . EXS. 79:1997;233-269.
38. Conforti G, Dominguez-Jimenez C, Zanetti A, Gimbrone MA, Cremona O, Marchisio PC, Dejana E. Human endothelial cells express integrin receptors on the luminal aspect of their membrane. Blood. 80:1992;437-446.
39. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 79:1994;1157-1164.
40. Brooks PC, Strömblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA. Antiintegrin αvβ3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest. 96:1995;1815-1822.
41. Pasqualini R, Koivunen E, Ruoslahti E. αv Integrins as receptors for tumor targeting by circulating ligands. Nature Biotech. 15:1997;542-546.
42. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. Angiostatin A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma . Cell. 79:1994;315-328.
43. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC, Yancopoulos GD. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell. 87:1996;1161-1169.
44. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 277:1997;55-60.
45. Kroesen BJ, Helfrich W, Bakker A, Wubbena AS, Bakker H, Kal HB, The TH, de Leij L. Reduction of EGP-2-positive pulmonary metastases by bispecific-antibody-redirected T cells in an immunocompetent rat model. Int J Cancer. 61:1995;812-818.
46. Kroesen BJ, ter Haar A, Spakman H, Willemse P, Sleijfer DT, de Vries EGE, Mulder NH, Berendsen HH, Limburg PC, The TH, de Leij L. Local antitumour treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells. Cancer Immunol Immunother. 37:1993;400-407.
47. Schultz-Hector S, Haghayegh S. β-Fibroblast growth factor expression in human and murine squamous cell carcinomas and its relationship to regional endothelial cell proliferation. Cancer Res. 53:1993;1444-1449.
48. Leek RD, Harris AL, Lewis CE. Cytokine networks in solid human tumors Regulation of angiogenesis . J Leukoc Biol. 56:1994;423-435.
49. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med. 2:1996;689-692.
50. Viola A, Lanzavecchia A. T cell activation determined by T cell receptor number and tunable thresholds. Science. 273:1996;104-106.
51. Thieme H, Aiello LP, Takagi H, Ferrara N, King GL. Comparative analysis of vascular endothelial growth factor receptors on retinal and aortic vascular endothelial cells. Diabetes. 44:1995;98-103.
52. Boucher Y, Salehi H, Witwer B, Harsh GR IV, Jain RK. Interstitial fluid pressure in intracranial tumours in patients and in rodents. Br J Cancer. 75:1997;829-836.
53. Pratesi G, Rodolfo M, Rovetta G, Parmiani G. Role of T cells and tumour necrosis factor in antitumour activity and toxicity of flavone acetic acid. Eur J Cancer. 26:1990;1079-1083.
54. Harris SR, Thorgeirsson UP. Flavone acetic acid stimulates nitric oxide and peroxynitrite production in subcutaneous mouse tumors. Biochem Biophys Res Commun. 235:1997;509-514.
55. O'Reilly SM, Rustin GJ, Farmer K, Burke M, Hill S, Denekamp J. Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma I. Clinical and vascular studies . Br J Cancer. 67:1993;1342-1345.